Combined Subcutaneous Recombinant &amp;alpha;&amp;ndash;Interferon and Interleukin&amp;ndash;2 in Metastatic Renal Cell Cancer: Results of the Multicentre All Ireland Immunotherapy Study Group

Rogers, Eamonn; Bredin, Hugh C.; Butler, Michael R.; Corcoran, M.; Egan, E. L.; Fennelly, J. J.; Grainger, Ronald G.; Aleer, S M; Dermott, T M; Mullins, Geoffrey C; Tanner, A; Twomey, Aongus; Thornhill, John

doi:10.1159/000052353

Cited by 15 publications

(6 citation statements)

References 15 publications

(32 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Combination regimens of IL‐2 and Inf‐α may produce an augmented response. The response rate is 18% ± 9 for IL‐2 with Inf‐α 4,8,14,15,20,22–27 . The CR rate is 5%.…”

Section: Induction Immunotherapymentioning

confidence: 90%

See 1 more Smart Citation

Current Clinical Practice of Induction and Maintenance Immunotherapy for Metastatic Renal Cell Carcinoma

Little

Young

2002

Int J Clinical Practice

View full text Add to dashboard Cite

SUMMARYCurrent systemic treatment of metastatic renal cell carcinoma revolves around the use of interleukin‐2 and interferon‐α, often in combination with 5‐fluorouracil. This article looks at the currently reported response rates for these modalities. It also looks at current practice as regards maintenance treatment, i.e. the continued therapeutic regimen following the initial response to the induction immunotherapy cycles.

show abstract

“…Combination regimens of IL‐2 and Inf‐α may produce an augmented response. The response rate is 18% ± 9 for IL‐2 with Inf‐α 4,8,14,15,20,22–27 . The CR rate is 5%.…”

Section: Induction Immunotherapymentioning

confidence: 90%

“…When patients who have exhibited a partial response to treatment are excluded from analysis, it is noteworthy that all the IL‐2 based regimens have similar CR rates of 4–6% 4,7–20,22–27,29–35 . However, Infa‐α shows a lower CR rate of 1% 3–6 .…”

Section: Induction Immunotherapymentioning

confidence: 99%

Current Clinical Practice of Induction and Maintenance Immunotherapy for Metastatic Renal Cell Carcinoma

Little

Young

2002

Int J Clinical Practice

View full text Add to dashboard Cite

show abstract

“…The median overall survival was found to be 15.8 months. 78 Following this, a 20-year follow-up study was conducted by the National Cancer Institute, where 9% of the patients showed complete response and only four developed disease recurrence. 79 The adverse effects of high-dose IL2 therapy demanded further research to be conducted exploring alternative dosing regimens.…”

Section: Cytokine Therapymentioning

confidence: 99%

The current status of immunobased therapies for metastatic renal-cell carcinoma

Sathianathen¹,

Krishna²,

Anderson³

et al. 2017

ITT

View full text Add to dashboard Cite

The management of metastatic renal-cell carcinoma (mRCC) represents an important clinical challenge. Since being approved in the early 1990s, aspecific immunotherapy has been a mainstay of treatment for mRCC and the only therapy that has demonstrated long-term cures for mRCC. However, in recent times there have been landmark advances made in the field of specific immunotherapy for a number of malignancies, including kidney cancer. This review outlines the range of immunobased agents currently available for the treatment of mRCC.

show abstract

“…In earlier studies cytokine therapy with interferon-alpha or interleukin-2 (IL-2) was shown to induce objective responses, although only achieving durable survival rates in a minority of patients with renal cell carcinoma [5]. Recent advances in understanding the molecular biology of common CCRCC have resulted in the development of drugs that target known molecular pathways involved in cellular proliferation and neoangiogenesis.…”

Section: Introductionmentioning

confidence: 99%

Metastases of Renal Cell Carcinoma to the Thyroid Gland with Synchronous Benign and Malignant Follicular Cell-Derived Neoplasms

Zamarrón

Abdulkader

Areses

et al. 2013

Case Reports in Oncological Medicine

View full text Add to dashboard Cite

Clear cell renal cell carcinoma (CCRCC) is the most common origin for metastasis in the thyroid. A 51-year-old woman was referred to our hospital for a subcarinal lesion. Ten years before, the patient had undergone a nephrectomy for CCRCC. Whole-body fluorodeoxyglucose positron emission tomography revealed elevated values in the thyroid gland, while the mediastinum was normal. An endoscopic ultrasonography-guided fine-needle aspiration biopsy of the mediastinal mass was consistent with CCRCC, and this was confirmed after resection. The thyroidectomy specimen also revealed lymphocytic thyroiditis, nodular hyperplasia, one follicular adenoma, two papillary microcarcinomas, and six foci of metastatic CCRCC involving both thyroid lobes. Curiously two of the six metastatic foci were located inside two adenomatoid nodules (tumor-in-tumor). The metastatic cells were positive for cytokeratins, CD10, epidermal growth factor receptor, and vascular endothelial growth factor receptor 2. No BRAF gene mutations were found in any of the primary and metastatic lesions. The patient was treated with sunitinib and finally died due to CCRCC distant metastases 6 years after the thyroidectomy. In CCRCC patients, a particularly prolonged survival rate may be achieved with the appropriate therapy, in contrast to the ominous prognosis typically found in patients with thyroid metastases from other origins.

show abstract

Combined Subcutaneous Recombinant α–Interferon and Interleukin–2 in Metastatic Renal Cell Cancer: Results of the Multicentre All Ireland Immunotherapy Study Group

Cited by 15 publications

References 15 publications

Current Clinical Practice of Induction and Maintenance Immunotherapy for Metastatic Renal Cell Carcinoma

Current Clinical Practice of Induction and Maintenance Immunotherapy for Metastatic Renal Cell Carcinoma

The current status of immunobased therapies for metastatic renal-cell carcinoma

Metastases of Renal Cell Carcinoma to the Thyroid Gland with Synchronous Benign and Malignant Follicular Cell-Derived Neoplasms

Contact Info

Product

Resources

About